Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986485 SAD and rBA in Healthy Adults
NCT07887763Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BMS-986485 (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Treatment Emergent Adverse Events at Day 29, Serious Adverse Events at Day 29 and 16 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BMS-986485
Beyond the preview
Go deeper on NCT07887763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887763.